Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium | NCT01109056 | Trialant
CompletedInterventionalPhase 2Updated Jun 25, 2012
Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium
ClinicalTrials.gov ID
NCT01109056
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
115Actual
Last Update Posted
Jun 25, 2012Estimated
Start Date
Jun 2010
Primary Completion Date
May 2011Actual
Completion Date
Jun 2011Actual
Brief Summary
This study will evaluate the safety and efficacy of Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) in patients with primary pterygium (abnormal growth on surface of eye).
Pterygium
cyclosporine ophthalmic emulsion 0.05%
Vehicle
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Have a pterygium in at least one eye that has not been previously removed with surgery
Exclusion Criteria:
Uncontrolled systemic disease
Active eye disease
Current or anticipated use of topical eye medications other than artificial tears.